Recipharm is Commencing Negotiations with LIDDS
News Apr 24, 2015
Recipharm has announced that it has commenced negotiations with the pharmaceutical company LIDDS regarding collaboration on manufacture of Liproca Depot® ahead of continued clinical development and a potential future market launch.
In a joint letter of intent the companies have explained their intention to initiate collaboration regarding scale-up, manufacture and quality assurance of LIDDS’ pharmaceutical products. Such a collaboration will initially focus on Liproca® Depot, a targeted treatment for prostate cancer that is currently in Phase II, but it may also include other products based on LIDDS’ unique technology platform. The letter of intent follows a so-called feasibility study performed by Recipharm. The results of this study confirm the possibility of developing a process for manufacture that ensures a high-quality end product.
“Collaboration with a manufacturing partner as renowned as Recipharm increases the power of attraction of our prostate-cancer product Liproca® Depot. A high-quality and cost-effective manufacturing process increases the chances of in the future being able to offer better treatment to patients with prostate cancer,” says Monica Wallter, LIDDS’ CEO.
“There is great potential in LIDDS’ technology platform for development of new treatments for diseases where local administration is desirable. We look forward to contributing with our technical expertise in the field of manufacture, so that cancer patients can in future be offered treatments associated with fewer side effects,” says Maria Lundberg General Manager Recipharm Pharmaceutical Development.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE
New Research Hub to Tackle Global Vaccination ChallengesNews
The University of Bristol will contribute to a new research hub to increase global immunisation coverage and improve response to viral outbreaks through the rapid and cost-effective deployment of vaccines.READ MORE